Supplementary Data 1 Legend from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma | Synapse
July 17, 2024
Supplementary Data 1 Legend from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Data legend for supplementary data 1, showing the process chart and raw whole slide images of multiplex IHC.